免疫グロブリン市場は、免疫疾患の有病率の増加、高齢者人口の増加、抗体治療の進歩により、予測期間中に347億ドルに達すると予想されます。組換えDNA技術などの製造技術の革新や、より標的を絞った効果的な治療法の開発が、市場の成長をさらに推進しています。しかし、免疫グロブリン療法の高いコストが課題となっており、特に低所得国や中所得国では、アクセスが制限される可能性があります。さらに、製品の安全性と品質に関する懸念、規制上のハードル、複雑な承認プロセスが課題です。サプライチェーンの混乱や不足も、在庫状況に影響を与える可能性があります。これらの課題にもかかわらず、継続的な研究開発と医療投資の増加が免疫グロブリン市場の継続的な成長を促進すると予想されます。
目次
Table of Content
1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Immunoglobulins Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Immunoglobulins Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Immunoglobulins Market - Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porter's Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Immunoglobulins Market
10.1. Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Immunoglobulins Market Size & Forecast 2024A-2034F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Product Type
11.3.1.1. IgG
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2. Market Share (%) 2024-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.2. IgA
11.3.1.2.1. By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3. IgM
11.3.1.3.1. By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.4. IgD
11.3.1.4.1. By Value (USD Million) 2024-2034F
11.3.1.4.2. Market Share (%) 2024-2034F
11.3.1.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.5. IgE
11.3.1.5.1. By Value (USD Million) 2024-2034F
11.3.1.5.2. Market Share (%) 2024-2034F
11.3.1.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.6. Others
11.3.1.6.1. By Value (USD Million) 2024-2034F
11.3.1.6.2. Market Share (%) 2024-2034F
11.3.1.6.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Route of Administration
11.3.2.1. Intravenous (IVIG)
11.3.2.1.1. By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Subcutaneous (SCIg)
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2. Market Share (%) 2024-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Others
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2. Market Share (%) 2024-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3. By Application
11.3.3.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.3.3.1.1. By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Multifocal Motor Neuropathy (MMN)
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2. Market Share (%) 2024-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Primary Immunodeficiency Disease (PID)
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2. Market Share (%) 2024-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.4. Secondary Immunodeficiency Disease (SID)
11.3.3.4.1. By Value (USD Million) 2024-2034F
11.3.3.4.2. Market Share (%) 2024-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.5. Guillain-Barre syndrome
11.3.3.5.1. By Value (USD Million) 2024-2034F
11.3.3.5.2. Market Share (%) 2024-2034F
11.3.3.5.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.6. Immune thrombocytopenic purpura (ITP)
11.3.3.6.1. By Value (USD Million) 2024-2034F
11.3.3.6.2. Market Share (%) 2024-2034F
11.3.3.6.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.7. Others
11.3.3.7.1. By Value (USD Million) 2024-2034F
11.3.3.7.2. Market Share (%) 2024-2034F
11.3.3.7.3. Y-o-Y Growth (%) 2024-2034F
12. North America Immunoglobulins Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Product Type
12.3.2. By Route of Administration
12.3.3. By Application
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Immunoglobulins Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Product Type
13.3.2. By Route of Administration
13.3.3. By Application
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Immunoglobulins Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Product Type
14.3.2. By Route of Administration
14.3.3. By Application
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Immunoglobulins Market Size & Forecast 2024A-2034F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Product Type
15.3.2. By Route of Administration
15.3.3. By Application
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Immunoglobulins Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Product Type
16.3.2. By Route of Administration
16.3.3. By Application
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Grifols
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. CSL Behring
18.3. Takeda Pharmaceutical Company
18.4. Octapharma AG
18.5. BioProduct Laboratory Ltd.
18.6. Kedrion Biopharma
18.7. AbbVie Inc.
18.8. Sanofi
18.9. Emergent BioSolutions
18.10. Polygel Laboratories
18.11. LFB Group
18.12. Shanghai RAAS Blood Products Co., Ltd.
18.13. Hualan Biological Engineering Inc.
18.14. BPL (British Plasma Laboratories)
18.15. Radius Health
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation
